NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nams · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$55.00
Consensus
$49.00
+58.3% upside
Low
$45.00
Median: $47 · Last Close: $30.95
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$49.00
58.3% upside
High Target
$55
77.7%
Low Target
$45
45.4%
Current Price
$30.95
as of today
Based on analyst price targets, the NAMS stock price prediction for the next 12 months ranges from $45 to $55. The consensus NAMS price forecast of $49.00 implies 58.3% upside from the current price of $30.95.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $29.41 | ↓ 5.00% |
1-day model range: $29.18–$29.64. Peak: $29.64 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $30 | -2.0% |
| 2028 | $30 | -3.2% |
| 2029 | $30 | -3.9% |
| 2030 | $30 | -4.4% |
| 2031 | — | -4.6% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NAMS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-02-19 | Guggenheim | Maintains | Buy→Buy |
| 2026-02-18 | Needham | Maintains | Buy→Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-12-16 | Stifel | Maintains | Buy→Buy |
| 2025-12-02 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2025-11-06 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-11-05 | Needham | Maintains | Buy→Buy |
| 2025-10-17 | Citigroup | Maintains | Buy→Buy |
| 2025-08-07 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-06-12 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on NewAmsterdam Pharma Company N.V. (NAMS) stock. Of the recent 29 rating actions, 0 were upgrades and 0 were downgrades. 10 analysts currently cover NAMS.
Analyst Recommendation Trends
NAMS analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$29M
↓ 93.0% YoY
Revenue Next Year
$171M
↑ 480.8% YoY
EPS This Year
$-1.81
EPS Next Year
$-1.39
↓ 22.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast NAMS EPS of $-1.81 for the current fiscal year, based on estimates from 10 analysts. The NAMS revenue forecast is $29M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NAMS stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NAMS price target is $49.00 (+58.3% upside), with an analyst consensus of Buy.
The NAMS short-term stock prediction for tomorrow is $29.41 (-5.00%). The NAMS stock price prediction for 2027 estimates an average of $30. The NAMS stock prediction for 2030 projects a range of $27–$32.
NewAmsterdam Pharma Company N.V. trades on NASDAQ under the ticker NAMS. The NAMS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 90% of covering analysts.
Frequently asked questions
NAMS forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month NAMS price target is $49.00, with a high forecast of $55.00 and a low of $45.00. The median price target is shown in the chart above when available. This implies +58.3% potential upside from the current price of $30.95.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.